However DDAVP is a V2 specific receptor agonist and has a minimal
oxytocin effect. There is not enough data on the use of DDAVP with breastfeeding but it has been demonstrated that DDAVP is released in very small amounts in breast milk . The data available for the use of DDAVP in pregnancy and postpartum are from a small number of studies or case reports: therefore any conclusions drawn are from limited evidence. As these two haemostatic drugs are both effective, relatively inexpensive with no major adverse events for the women and newborns, large clinical trials and further investigation in this type of population are required for both drugs to reach more definitely selleckchem conclusions. Pregnancy can be associated with a risk of bleeding complications for women with IBD and their
affected babies. There is lack of data on the risk of miscarriage and antepartum haemorrhage in affected women. An increased risk of these obstetric complications has only been clearly reported in women with severe deficiency of fibrinogen and factor XIII. However, the risk of primary and secondary PPH is significantly increased in women with all types of bleeding disorders. For the neonates affected with severe bleeding disorders such as severe haemophilia, there is a significant risk of head bleeding in relation to delivery especially with traumatic Selleckchem VX-765 and instrumental deliveries. A multidisciplinary team approach with advanced
individualized management plan can minimize these risks and improve quality of care. The combined expertise of the obstetric and the haemophilia team help early identification of obstetric and bleeding risks, thus prevention and a prompt treatment of bleeding complications. Research and clinical interest in the field of women with IBD in the last two decades has led find more to an increased awareness among clinicians and better appreciation of maternal and neonatal bleeding risks. Patient advocacy organizations and international societies have been crucial and worked closely to promote patient care through awareness campaigns and supporting research and education in the field. Further research is necessary and ongoing to address controversial aspects of care and improve choices and quality of care for affected women. This supplement was sponsored by CSL Behring. The University of Virginia has received honoraria on behalf of Prof. Andrea H. James from CSL Behring. Prof. Flora Peyvandi has received speaker honoraria from Novo Nordisk, Bayer, Baxter, CSL Behring, and Biotest. Ms Debra Pollard has received consultancy fees for Novo Nordisk, Bayer, and Pfizer. Prof. Augusto B. Federici has received consultancy fees (e.g. advisory boards) from: Baxter, CSL Behring, Grifols, Laboratories Francais de Fractionnement et des Biotechnologies (LFB) and Octapharma. Authors Dr RA Kadir and J Davies have no disclosures.